WO2020262755A1 - 장관면역 조절을 위한 신규한 프로바이오틱 조성물 - Google Patents
장관면역 조절을 위한 신규한 프로바이오틱 조성물 Download PDFInfo
- Publication number
- WO2020262755A1 WO2020262755A1 PCT/KR2019/009117 KR2019009117W WO2020262755A1 WO 2020262755 A1 WO2020262755 A1 WO 2020262755A1 KR 2019009117 W KR2019009117 W KR 2019009117W WO 2020262755 A1 WO2020262755 A1 WO 2020262755A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lactobacillus
- present
- subspecies lactis
- animalis subspecies
- bifidobacterium
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 141
- 239000006041 probiotic Substances 0.000 title abstract description 22
- 235000018291 probiotics Nutrition 0.000 title abstract description 22
- 230000000529 probiotic effect Effects 0.000 title abstract description 17
- 230000008944 intestinal immunity Effects 0.000 title abstract description 7
- 241001134770 Bifidobacterium animalis Species 0.000 claims abstract description 75
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 73
- 229940118852 bifidobacterium animalis Drugs 0.000 claims abstract description 73
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 71
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 71
- 241001468157 Lactobacillus johnsonii Species 0.000 claims abstract description 64
- 239000004480 active ingredient Substances 0.000 claims abstract description 46
- 206010061218 Inflammation Diseases 0.000 claims abstract description 16
- 230000004054 inflammatory process Effects 0.000 claims abstract description 16
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 75
- 238000002360 preparation method Methods 0.000 claims description 55
- 235000013305 food Nutrition 0.000 claims description 35
- 238000011282 treatment Methods 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 27
- 241000186660 Lactobacillus Species 0.000 claims description 23
- 229940039696 lactobacillus Drugs 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 241000186000 Bifidobacterium Species 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 12
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 7
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 7
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 230000000968 intestinal effect Effects 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 206010074063 Ischaemic enteritis Diseases 0.000 claims description 2
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims 2
- 229940009289 bifidobacterium lactis Drugs 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 abstract description 6
- 208000028774 intestinal disease Diseases 0.000 abstract 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 186
- 241000894006 Bacteria Species 0.000 description 101
- 239000004310 lactic acid Substances 0.000 description 93
- 235000014655 lactic acid Nutrition 0.000 description 93
- 210000004027 cell Anatomy 0.000 description 44
- 206010009887 colitis Diseases 0.000 description 33
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 31
- 230000000694 effects Effects 0.000 description 28
- 210000001072 colon Anatomy 0.000 description 26
- 238000009472 formulation Methods 0.000 description 25
- 102000004127 Cytokines Human genes 0.000 description 22
- 108090000695 Cytokines Proteins 0.000 description 22
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 18
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 18
- 229960001940 sulfasalazine Drugs 0.000 description 18
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 18
- 238000010171 animal model Methods 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 14
- 102100040247 Tumor necrosis factor Human genes 0.000 description 14
- 230000000770 proinflammatory effect Effects 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 11
- 108090001005 Interleukin-6 Proteins 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 230000036541 health Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 210000002429 large intestine Anatomy 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 235000013376 functional food Nutrition 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- OGQHCUYSWDOIMP-UHFFFAOYSA-N 7-(diethylamino)-n-[2-[(2-iodoacetyl)amino]ethyl]-2-oxochromene-3-carboxamide Chemical compound C1=C(C(=O)NCCNC(=O)CI)C(=O)OC2=CC(N(CC)CC)=CC=C21 OGQHCUYSWDOIMP-UHFFFAOYSA-N 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 235000013351 cheese Nutrition 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 235000021109 kimchi Nutrition 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920002472 Starch Chemical class 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 229920002678 cellulose Chemical class 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 208000035861 hematochezia Diseases 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 3
- 229960004963 mesalazine Drugs 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- 108050003558 Interleukin-17 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 210000000068 Th17 cell Anatomy 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000001913 cellulose Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 210000004921 distal colon Anatomy 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000002175 goblet cell Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002962 histologic effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000017306 interleukin-6 production Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000003780 keratinization Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- -1 pH adjusters Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000013580 sausages Nutrition 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241001237745 Salamis Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 230000033540 T cell apoptotic process Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241001489212 Tuber Species 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 235000020299 breve Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000014651 chocolate spreads Nutrition 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000014156 coffee whiteners Nutrition 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- HJUFTIJOISQSKQ-UHFFFAOYSA-N fenoxycarb Chemical compound C1=CC(OCCNC(=O)OCC)=CC=C1OC1=CC=CC=C1 HJUFTIJOISQSKQ-UHFFFAOYSA-N 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011868 grain product Nutrition 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000004964 innate lymphoid cell Anatomy 0.000 description 1
- 230000019189 interleukin-1 beta production Effects 0.000 description 1
- 230000021995 interleukin-8 production Effects 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000014594 pastries Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000015175 salami Nutrition 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Chemical class 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000015149 toffees Nutrition 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/362—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G1/00—Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/30—Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/32—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds
- A23G1/42—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G1/423—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/366—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
- A23G4/12—Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G4/123—Chewing gum characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
- A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
- A23G9/36—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G9/363—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/151—Johnsonii
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
Definitions
- the present invention relates to a novel probiotic composition for regulating intestinal immunity, and more specifically, Lactobacillus johnsonii , Lactobacillus plantarum , and Bifidobacterium animalis subspecies rock Bifidobacterium animalis subspecies lactis ) It is for a composition for preventing, improving, or treating inflammatory bowel disease containing as an active ingredient.
- IBD Inflammatory bowel disease
- UC ulcerative colitis
- CD Crohn's disease
- ulcerative colitis mainly invades the mucous membrane, and the cause of the large intestine, which often forms patting or ulcers, is unknown.
- UC ulcerative colitis
- Crohn's disease Crohn's disease
- ⁇ Stenosis and lesion
- the cause of the inflammatory bowel disease has not been specifically identified yet, but it is known that abnormalities in immune function are involved, and immunological factors involved in this include innate immunity, production of cytokines, activation of CD4, etc. This is known. In particular, cytokines are known to play an important role, and tumor nerosis cytokine (TNF- ⁇ ), interluekin (IL)-1, IL-6, and IL-8 production at the site of inflammation are ulcerative. It was confirmed that it was significantly increased in patients with colitis and Crohn's disease.
- TNF- ⁇ a major pro-inflammatory cytokine
- Anti-TNF- ⁇ antibodies such as infliximab and adalimumab have been approved to treat patients with severe colitis, because inhibition of TNF- ⁇ is highly effective in regulating intestinal immunity by preventing apoptosis of mucosal T lymphocytes (non- Patent Document 1).
- IL-1 ⁇ recruits granulocytes, causes colon inflammation, activates CD4+ Th17 cells, and secretes IL-17 (Non-Patent Document 2). It is known that neutrophil infiltration is fundamentally necessary for the progression of chronic inflammation.
- IL-6 promotes neutrophil migration to the colitis (colitis) area (Non-Patent Document 3).
- drugs used to treat inflammatory bowel disease include steroidal immunosuppressants, 5-aminosalicylic acid (5-ASA) drugs that block the production of prostaglandins (e.g., sulfasalazine). , Mesalazine, etc. are being used.
- 5-ASA 5-aminosalicylic acid
- anti-inflammatory agents and immunosuppressants are prescribed to alleviate colitis, but it is well known that there are undesirable side effects such as nausea, vomiting, headache, hemolytic anemia, and male infertility.
- Non-Patent Document 1 Atreya R, Zimmer M, Bartsch B, et al.: Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14(+) macrophages. Gastroenterology 2011;141:2026-2038.
- TNF tumor necrosis factor
- Non-Patent Document 2 Coccia M, Harrison OJ, Schiering C, et al.: IL-1beta mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells. J Exp Med 2012;209:1595-1609.
- Non-Patent Document 3 Wang Y, Wang K, Han GC, et al.: Neutrophil infiltration favors colitis-associated tumorigenesis by activating the interleukin-1 (IL-1)/IL-6 axis. Mucosal Immunol 2014;7:1106-1115.
- IL-1 interleukin-1
- the present inventors have made extensive research efforts to develop a safe and effective therapeutic agent for inflammatory bowel disease, and as a result, it was confirmed that the prevention and treatment effect of inflammatory bowel disease (IBD) was remarkably increased by using the combination of three types of lactic acid bacteria unique to the present invention.
- the present invention was completed by confirming that such an effect is at an excellent level even compared with sulfasalazine, which is commonly used as a drug for treating IBD.
- the object of the present invention is Lactobacillus johnsonii , Lactobacillus plantarum , and Bifidobacterium animalis subspecies lactis ( Bifidobacterium animalis subspecies lactis ) to provide a pharmaceutical composition for the prevention or treatment of inflammatory bowel disease containing as an active ingredient.
- Another object of the present invention is to provide a food composition for preventing or improving inflammatory bowel disease, comprising Lactobacillus Johnsoni, Lactobacillus plantarum, and Bifidobacterium animalis subspecies lactis as active ingredients.
- Another object of the present invention is to provide an anti-inflammatory composition (pharmaceutical composition or food composition) comprising Lactobacillus Johnsoni, Lactobacillus plantarum, and Bifidobacterium animalis subspecies lactis as an active ingredient. will be.
- Another object of the present invention is Lactobacillus johnsonii (Lactobacillus johnsonii), Lactobacillus plantarum, and Bifidobacterium animalis subspecies lactis (Lactobacillus johnsonii) for preparing a preparation for the prevention or treatment of inflammatory bowel disease ( It is to provide a use of a composition containing Bifidobacterium animalis subspecies lactis) as an active ingredient.
- Another object of the present invention is a composition comprising Lactobacillus johnsonii, Lactobacillus plantarum, and Bifidobacterium animalis subspecies lactis as an active ingredient. It is to provide a method of treating inflammatory bowel disease comprising administering an effective amount to an individual in need thereof.
- Another object of the present invention is Lactobacillus johnsonii (Lactobacillus johnsonii), Lactobacillus plantarum, and Bifidobacterium animalis subspecies lactis (Bifidobacterium animalis subspecies lactis) for preparing an anti-inflammatory agent. ) To provide the use of the composition containing as an active ingredient.
- Another object of the present invention is a composition comprising Lactobacillus johnsonii, Lactobacillus plantarum, and Bifidobacterium animalis subspecies lactis as an active ingredient It is to provide a method of inhibiting inflammation comprising administering an effective amount of the compound to a subject in need thereof.
- the present invention is Lactobacillus johnsonii ( Lactobacillus johnsonii ), Lactobacillus plantarum ( Lactobacillus plantarum ), and Bifidobacterium animalis subspecies lactis ( Bifidobacterium animalis subspecies lactis ) as an active ingredient It provides a pharmaceutical composition for the prevention or treatment of inflammatory bowel disease comprising as.
- the present invention is Lactobacillus johnsonii ( Lactobacillus johnsonii ), Lactobacillus plantarum ( Lactobacillus plantarum ), and Bifidobacterium animalis subspecies lactis ( Bifidobacterium animalis subspecies lactis ) provides a pharmaceutical composition for the prevention or treatment of inflammatory bowel disease consisting of an active ingredient.
- the present invention is Lactobacillus johnsonii ( Lactobacillus johnsonii ), Lactobacillus plantarum ( Lactobacillus plantarum ), and Bifidobacterium animalis subspecies lactis ( Bifidobacterium animalis subspecies lactis ) provides a pharmaceutical composition for the prevention or treatment of inflammatory bowel disease consisting essentially of as an active ingredient.
- the present invention is a food composition for preventing or improving inflammatory bowel disease comprising Lactobacillus Johnsoni, Lactobacillus plantarum, and Bifidobacterium animalis subspecies lactis as active ingredients Provides.
- the present invention provides a food composition for preventing or improving inflammatory bowel disease comprising Lactobacillus Johnsoni, Lactobacillus plantarum, and Bifidobacterium animalis subspecies lactis as active ingredients.
- the present invention provides a food composition for the prevention or improvement of inflammatory bowel disease consisting essentially of Lactobacillus Johnsoni, Lactobacillus plantarum, and Bifidobacterium animalis subspecies lactis as active ingredients.
- an anti-inflammatory composition (pharmaceutical composition or food composition) comprising Lactobacillus Johnsoni, Lactobacillus plantarum, and Bifidobacterium animalis subspecies lactis as active ingredients Provides.
- an anti-inflammatory composition consisting of Lactobacillus Johnsoni, Lactobacillus plantarum, and Bifidobacterium animalis subspecies lactis as an active ingredient.
- an anti-inflammatory composition consisting essentially of Lactobacillus Johnsoni, Lactobacillus plantarum, and Bifidobacterium animalis subspecies lactis as active ingredients.
- the present invention is Lactobacillus johnsonii (Lactobacillus johnsonii), Lactobacillus plantarum (Lactobacillus plantarum) and Bifidobacterium no for preparing a preparation for preventing or treating inflammatory bowel disease. It provides the use of a composition containing the Malis subspecies lactis (Bifidobacterium animalis subspecies lactis) as an active ingredient.
- the present invention is Lactobacillus johnsonii (Lactobacillus johnsonii), Lactobacillus plantarum (Lactobacillus plantarum) and Bifidobacterium animalis subspecies lactis (Bifidobacterium animalis subspecies lactis) as active ingredients It provides a method for treating inflammatory bowel disease, comprising administering an effective amount of a composition comprising it to an individual in need thereof.
- the present invention is Lactobacillus johnsonii (Lactobacillus johnsonii), Lactobacillus plantarum, and Bifidobacterium animalis subspecies lactis for preparing an anti-inflammatory agent. It provides a use of a composition containing (Bifidobacterium animalis subspecies lactis) as an active ingredient.
- the present invention is effective Lactobacillus johnsonii (Lactobacillus johnsonii), Lactobacillus plantarum, and Bifidobacterium animalis subspecies lactis (Bifidobacterium animalis subspecies lactis). It provides a method for inhibiting inflammation comprising administering to an individual in need thereof an effective amount of a composition comprising as an ingredient.
- the term'comprising' in the present invention is used in the same way as'containing' or'as a feature', and does not exclude additional component elements or method steps that are not mentioned in the composition or method. .
- the term'consisting of' is used in the same way as'consisting of', and means excluding additional elements, steps, or ingredients that are not separately described.
- the term'essentially consisting of' or'essentially consisting of' means, in the scope of a composition or method, a component element or step that does not substantially affect its basic properties in addition to the described component elements or steps. Means to include.
- range value includes the corresponding boundary value, that is, it means that all values above the lower limit and below the upper limit are included.
- the description of the range form is merely for convenience and simplicity and should not be construed as an inflexible limitation to the scope of the invention. Accordingly, the description of a range should be considered to specifically disclose all possible subranges, as well as individual numerical values within the range.
- a description of a range such as 7 to 170 may refer to individual values within the range, e.g. 9, 27, 35, 101, and 155, as well as 10 to 127, 23 to 35, 80 to 100, 50. It should be regarded as specifically disclosed subranges such as to 169 and the like. This applies regardless of the width of the range.
- probiotics is defined as a microorganism that gives a health benefit to a host when administered in an appropriate amount.
- the established safety and beneficial effects on human health have led to the emergence of probiotics as substitutes or supplements for medicines.
- the advantage of probiotics is that they have few side effects.
- the present inventors screened the individual efficacy of each strain in various aspects targeting various lactic acid bacteria strains isolated from infant feces, kimchi, and cheese, and also performed efficacy evaluation in various aspects using various strains in various combinations.
- the present inventors Lactobacillus johnsonii IDCC9203 (KCTC 10923BP), Lactobacillus plantarum IDCC3501 (KCTC 13586BP) and Bifidobacterium
- KCTC 13587BP Lactobacillus johnsonii IDCC9203
- KCTC 13586BP Lactobacillus plantarum IDCC3501
- Bifidobacterium When the combination of three strains of animalis subspecies lactis IDCC4301 (KCTC 13587BP) was used in combination, an unexpected synergistic effect was specifically confirmed in anti-inflammatory efficacy, as well as practical therapeutic efficacy for inflammatory bowel disease (IBD) in terms of pharmacology.
- IBD inflammatory bowel disease
- the therapeutic effect of the present invention was superior to that of sulfasalazine, a known IBD treatment drug.
- the characteristics of probiotics are strain-dependent even in bacteria of the same species, and considering that it is difficult to prepare a composition that exhibits excellent performance for all probiotic requirements, the composition of the three lactic acid bacteria of the present invention and the remarkable effect identified by the present inventors are technical.
- the mixture of three strains of the present invention exhibited excellent therapeutic effects even at a smaller dose.
- Lactobacillus johnsonii Lactobacillus johnsonii
- Lactobacillus plantarum Lactobacillus plantarum
- Bifidobacterium animalis subspecies lactis Bifidobacterium animalis subspecies lactis
- the present invention provides a pharmaceutical composition for preventing or treating inflammatory bowel disease or a food composition for preventing or improving inflammatory bowel disease composed of the above three strains.
- the present invention provides a pharmaceutical composition for preventing or treating inflammatory bowel disease or a food composition for preventing or improving inflammatory bowel disease, which is essentially composed of the three strains.
- the present invention is Lactobacillus Johnsoni IDCC9203 ( Lactobacillus johnsonii IDCC9203) strain, Lactobacillus plantarum IDCC3501 ( Lactobacillus plantarum IDCC3501) strain and Bifidobacterium animalis subspecies Lactose IDCC4301 ( Bifidobacterium animalis subspecies lactis IDCC4301) provides a probiotic composition comprising the strain (in an effective amount), and also provides a probiotic composition consisting of the three strains (in an effective amount), and the 3 It provides a probiotic composition consisting essentially of a species strain (in an effective amount).
- the present invention is Lactobacillus Johnsoni IDCC9203 ( Lactobacillus johnsonii IDCC9203) strain, Lactobacillus plantarum IDCC3501 ( Lactobacillus plantarum IDCC3501) strain and Bifidobacterium animalis subspecies Lactis IDCC4301 ( Bifidobacterium animalis subspecies lactis IDCC4301) provides a pharmaceutical composition for preventing or treating inflammatory bowel disease containing the strain as an active ingredient, and also providing a food composition for preventing or improving inflammatory bowel disease containing the three strains as an active ingredient. do.
- the present invention provides a Lactobacillus Johnsoni IDCC9203 ( Lactobacillus johnsonii IDCC9203) strain, Lactobacillus plantarum IDCC3501 ( Lactobacillus plantarum IDCC3501) strain and Bifidobacterium animalis subspecies Lactis IDCC4301 ( Bifidobacterium animalis subspecies lactis IDCC4301) provides a pharmaceutical composition for the prevention or treatment of inflammatory bowel disease consisting of the strain, and also provides a food composition for preventing or improving inflammatory bowel disease consisting of the three strains.
- the present invention provides a Lactobacillus Johnsoni IDCC9203 ( Lactobacillus johnsonii IDCC9203) strain, Lactobacillus plantarum IDCC3501 ( Lactobacillus plantarum IDCC3501) strain and Bifidobacterium animalis subspecies Lactis IDCC4301 ( Bifidobacterium animalis subspecies lactis IDCC4301) provides a pharmaceutical composition for the prevention or treatment of inflammatory bowel disease consisting essentially of the strain, and also provides a food composition for preventing or improving inflammatory bowel disease consisting essentially of the three strains.
- The'inflammatory bowel disease' is not particularly limited as long as it is a disease known in the art that an inflammatory condition in the intestine is a major pathology, but is preferably a group consisting of Crohn's disease, ulcerative colitis, intestinal Behcet's disease, and ischemic enteritis. It may be selected from.
- composition of the present invention is not limited thereto, but the three lactic acid bacteria (Lactobacillus Johnsoni, Lactobacillus plantarum, Bifidobacterium animalis subspecies lactis) are formulated to exist in one container in the form of a mixture.
- each of the three lactic acid bacteria may be packaged and provided in separate containers, but may be formulated to be administered simultaneously or sequentially upon use.
- the three types of lactic acid bacteria of the present invention may be provided in the form of a mixture, and as an example of this embodiment, the present invention is Lactobacillus johnsonii , Lactobacillus plantarum. ), and Bifidobacterium animalis subspecies lactis ( Bifidobacterium animalis subspecies lactis ) It provides a pharmaceutical composition for preventing or treating inflammatory bowel disease (or a food composition for preventing or improving the disease) comprising a mixed lactic acid bacteria as an active ingredient.
- the effective amount of the colony forming unit (CFU) of each strain may be determined by the purpose (disease prevention, health or therapeutic treatment) or needs by a person skilled in the art, and according to the final formulation. Can be determined.
- 1 ⁇ 10 5 to 1 ⁇ 10 15 (number of bacteria or CFU) per 1 g (or ml) of the total composition are added to each of the three strains of the present invention when preparing food or medicine It may be, and preferably, it may be added in an amount of 1 ⁇ 10 6 to 1 ⁇ 10 13 , but is not limited thereto.
- the daily intake of the composition containing the live cells or dead cells thereof is 1 ⁇ 10 5 to 1 ⁇ 10 10 CFU/kg, preferably 1 ⁇ 10 6 to 1 ⁇ 10 9 based on the total number of cells. It may be CFU/kg, and the intake may be taken once a day, or may be divided several times, but is not limited thereto.
- the relative ratio of the three lactic acid bacteria provided is not particularly limited as long as it exhibits the desired effect (anti-inflammatory effect or inflammatory bowel disease prevention/treatment/improvement effect) in the present invention.
- the composition ratio of L. johnsonii IDCC9203: L. plantarum IDCC3501: B. animalis subspecies lactis IDCC4301 is 1 ⁇ 100:1 ⁇ 100:1 ⁇ 100 based on cfu/g (or cfu/ml).
- composition ratio of L. johnsonii IDCC9203: L. plantarum IDCC3501: B. animalis subspecies lactis IDCC4301 may be composed in a ratio of 1:7:2 based on cfu/g (or cfu/ml) units. .
- the composition ratio of the three lactic acid bacteria may be composed in a ratio of 1:1:1 based on cfu/g (or cfu/ml).
- the three lactic acid bacteria may be provided in the form of live cells or dead cells, respectively.
- Methods for treating bacteria to provide a probiotic preparation in the art are well known in the art, and if the bacteria are in a living form, the provided form is not particularly limited. For example, after culturing the strains, cell pellets are recovered, used as such, or processed by a desired means by, for example, concentration or/and freeze-drying, and added to the manufacture of pharmaceutical or edible products. Sometimes, probiotic formulations can be subjected to an immobilization or encapsulation process to improve longevity. Several bacteria immobilization or encapsulation techniques are known in the art.
- the term “dead cells” refers to cells that have been sterilized by heating, pressurization, or drug treatment. If it is by the method of killing lactic acid bacteria known in the art, the method for preparing the dead cells is not particularly limited, and as an example, the dead cells of the present invention may be produced by a method of killing (by heat treatment) including heat treatment.
- the heat treatment may be performed on only the live cells separated from the culture solution, or may be performed on the culture solution containing the living cells.
- the heat treatment temperature is a condition in which the properties of the cells are maintained and other general bacteria are sterilized, the temperature condition is not particularly limited, but may be performed at 80°C to 150°C, preferably 80°C to 110°C. I can.
- the heat treatment time is not particularly limited as long as it is a condition in which a person skilled in the art can obtain the desired manufacturing quality in consideration of the temperature condition, but may proceed from 5 minutes to 15 minutes as an example.
- distilled water may be added to and mixed with live cells before the heat treatment.
- the dead cells may be subjected to any additional process for the production of a dead cell preparation (formulation), and for example, concentration, drying, etc. may be performed.
- the type of drying is not particularly limited as long as it is a method used for drying lactic acid bacteria in the art, but may be, for example, hot (wind) drying or freeze drying.
- the present invention comprises Lactobacillus johnsonii , Lactobacillus plantarum , and Bifidobacterium animalis subspecies lactis as an active ingredient. It provides an anti-inflammatory pharmaceutical composition or food composition.
- the present invention is Lactobacillus Johnsoni IDCC9203 ( Lactobacillus johnsonii IDCC9203) strain, Lactobacillus plantarum IDCC3501 ( Lactobacillus plantarum IDCC3501) strain and Bifidobacterium animalis subspecies Lactis IDCC4301 ( Bifidobacterium animalis subspecies lactis IDCC4301) provides an anti-inflammatory pharmaceutical composition or food composition comprising the strain as an active ingredient.
- the pharmaceutical composition of the present invention may contain live or dead cells of the three lactic acid bacteria described above alone, or may further contain one or more pharmaceutically acceptable carriers, excipients, or diluents.
- pharmaceutically acceptable is a non-toxic composition that is physiologically acceptable and does not inhibit the action of the active ingredient when administered to humans, and does not usually cause allergic reactions such as gastrointestinal disorders, dizziness, or similar reactions.
- the pharmaceutically acceptable carrier may further include, for example, a carrier for oral administration or a carrier for parenteral administration.
- Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like.
- the pharmaceutical composition of the present invention can be administered to mammals including humans by any method. For example, it can be administered orally or parenterally (for example, a coating method).
- the pharmaceutical composition of the present invention can be formulated as a formulation for oral administration or parenteral administration according to the administration route as described above.
- the composition of the present invention is known in the art as a freeze-dried powder, capsule, granule, tablet, pill, dragee, liquid, gel, syrup, slurry, suspension, wafer, etc. It can be formulated using a conventional method.
- oral preparations may be provided by blending the active ingredient with a solid excipient and then adding a suitable adjuvant thereto and then processing it into a capsule or the like.
- excipients examples include sugars including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol and maltitol, and starches including corn starch, wheat starch, rice starch and potato starch, cellulose, Fillers such as celluloses including methylcellulose, sodium carboxymethylcellulose and hydroxypropylmethyl-cellulose, gelatin, and polyvinylpyrrolidone may be included.
- the pharmaceutical composition of the present invention may further include an anti-aggregating agent, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent and a preservative, and the like, but is not limited thereto.
- the food composition of the present invention includes all foods in the usual sense, and can take all forms such as functional food, nutritional supplement, health food, and food additives. Include. Food compositions of this type can be prepared in various forms according to conventional methods known in the art.
- the food composition of the present invention may contain a health functional food.
- the term'health functional food' used in the present invention refers to food manufactured and processed in the form of tablets, capsules, powders, granules, liquids and pills, using raw materials or ingredients having useful functions for the human body.
- “functionality” means obtaining useful effects for health purposes such as controlling nutrients or physiological effects on the structure and function of the human body.
- the health functional food of the present invention can be prepared by a method commonly used in the art, and at the time of manufacture, it can be prepared by adding raw materials and ingredients commonly added in the art.
- the formulation of the health functional food may be prepared without limitation as long as it is a formulation recognized as a health functional food.
- the food composition of the present invention can be prepared in various forms, and unlike general drugs, it has the advantage of not having side effects that may occur when taking drugs for a long period of time using food as a raw material. Is possible.
- the food composition of the present invention contains various nutrients, vitamins, electrolytes, flavoring agents, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, etc. can do.
- it may contain the flesh of the fruit.
- These ingredients may be used independently or in combination. Although the ratio of these additives is not very important, it is generally selected from 0.01 to 0.3 parts by weight per 100 parts by weight of the food composition of the present invention, but is not limited thereto.
- the food composition of the present invention may contain various flavoring agents or natural carbohydrates as additional components.
- the carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
- sweetener natural sweeteners such as taumatin and stevia extract, and synthetic sweeteners such as saccharin and aspartame can be used.
- the ratio of the natural carbohydrate may be generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the composition of the present invention, but is not limited thereto.
- the food composition of the present invention may also be provided in the form of fermented food.
- Three lactic acid bacteria of the present invention are dairy products, yogurt, curd (curd), cheese (eg, quark, cream, processed, soft and hard), fermented milk, milk powder, fermented products based on milk, ice cream, fermented grain products ( fermented cereal based product), milk based powder, beverages, dressings and pet food.
- "edible product” is in the broadest sense, including all types of products, in all forms of provision, that can be consumed by animals, excluding pharmaceutical products and veterinary products herein.
- examples of other edible products include meat products (e.g. liver paste, sausage, salami sausage or meat spreads), chocolate spreads, fillings (e.g.
- dietary supplements also include nutraceuticals known as food extracts with medicinal efficacy on human health.
- Animal dietary feed is also included in the scope of the present invention.
- the composition of the present invention can also be used as a component of other food products.
- Lactobacillus johnsonii (Lactobacillus johnsonii), Lactobacillus plantarum, and Bifidobacterium animalis subspecies lactis (Bifidobacterium animalis subspecies) for preparing a preparation for preventing or treating inflammatory bowel disease. lactis) as an active ingredient.
- the present invention provides the use of a composition comprising the above three strains as an active ingredient for preparing a preparation for preventing or treating inflammatory bowel disease, and the present invention prepares a preparation for preventing or treating inflammatory bowel disease It provides the use of a composition consisting essentially of the three strains as an active ingredient for.
- the present invention provides an effective amount of a composition comprising Lactobacillus johnsonii, Lactobacillus plantarum, and Bifidobacterium animalis subspecies lactis as an active ingredient. It provides a method of treating inflammatory bowel disease comprising administering to an individual in need.
- the present invention is effective Lactobacillus johnsonii (Lactobacillus johnsonii), Lactobacillus plantarum, and Bifidobacterium animalis subspecies lactis (Bifidobacterium animalis subspecies lactis) for preparing an anti-inflammatory agent It provides the use of a composition comprising as an ingredient.
- the present invention provides a use of a composition comprising the three strains as an active ingredient for preparing an anti-inflammatory agent, and essentially uses the three strains as an active ingredient for preparing an anti-inflammatory agent. It provides the use of the composition to be constituted.
- the present invention provides an effective amount of a composition comprising Lactobacillus johnsonii, Lactobacillus plantarum, and Bifidobacterium animalis subspecies lactis as an active ingredient. It provides a method of inhibiting inflammation comprising the step of administering to an individual in need thereof.
- Anti-inflammatory' in the present invention inhibits molecular and cellular inflammatory reactions such as infiltration of immune cells, the secretion of pro-inflammatory factors such as pro-inflammatory cytokines, prostaglandins and nitrogen monoxide (NO), and increases erythema, keratinization, and skin thickness. It refers to preventing, alleviating or improving symptoms such as hyperemia, fever, and pain.
- The'inflammation suppression' of the present invention inhibits molecular and cellular inflammatory reactions such as infiltration of immune cells, proinflammatory cytokines, secretion of pro-inflammatory factors such as prostaglandin and nitrogen monoxide (NO), It refers to preventing, alleviating or improving symptoms such as erythema, keratinization, skin thickness increase, congestion, fever, and pain.
- The'effective amount' of the present invention refers to an amount showing an effect of improving, treating, preventing, detecting, diagnosing, or inhibiting or reducing inflammation and/or inflammatory bowel disease, when administered to an individual
- The'individual' may be an animal, preferably an animal including a mammal, particularly a human, and may be a cell, tissue, organ, etc. derived from an animal.
- the individual may be a patient in need of the effect.
- The'treatment' of the present invention refers generically to improving symptoms of inflammation and/or inflammatory bowel disease or inflammation and/or inflammatory bowel disease, which cures or substantially prevents inflammation and/or inflammatory bowel disease , Or improving the condition, and alleviating, curing, or preventing one symptom or most of the symptoms resulting from the disease, but is not limited thereto.
- composition comprising the combination of three lactic acid bacteria unique to the present invention has a remarkable preventive and therapeutic effect on inflammatory bowel disease (IBD), and in particular, this effect is pharmacologically superior even compared to a known IBD therapeutic drug (for example, sulfasalazine).
- IBD inflammatory bowel disease
- the composition of the present invention has a great advantage as a safe composition with very little risk of side effects due to the nature of a probiotic composition.
- Lactobacillus johnsonii IDCC9203 No. 6
- Lactobacillus plantarum IDCC3501 No. 7
- Bifidobacterium animalis subspecies lactis IDCC4301 No. 14
- Lactobacillus johnsonii KCTC 3801 T Lactobacillus plantarum KCTC 3108 T
- Bifidobacterium animalis ssp. lactis IDCC KCTC 3219 T respectively, to compare the inhibitory effect on TNF- ⁇ increased in Raw 264.7 cells by LPS treatment (DEX: dexamethasone).
- Figure 3 is a mixture of Type strains ( Lactobacillus johnsonii KCTC 3801 T , Lactobacillus plantarum KCTC 3108 T , Bifidobacterium) having a homogeneous relationship with the composition of the present invention animalis ssp. lactis IDCC KCTC 3219 T ) was administered to LPS-treated Raw 264.7 cells, and the result of confirming the degree of change in IL-6 level is shown.
- Type strains Lactobacillus johnsonii KCTC 3801 T , Lactobacillus plantarum KCTC 3108 T , Bifidobacterium
- FIG. 4 shows the results confirming that increased IL-1 ⁇ in Raw 264.7 cells by LPS treatment was inhibited by the treatment of the three lactic acid bacteria preparations of the present invention.
- Figure 5 is a mixture of Type strains ( Lactobacillus johnsonii KCTC 3801 T , Lactobacillus plantarum KCTC 3108 T , Bifidobacterium) having a homogeneous relationship with the composition of the present invention animalis ssp. lactis IDCC KCTC 3219 T ) was administered to LPS-treated Raw 264.7 cells, and the result of confirming the degree of change in IL-1 ⁇ level is shown.
- Type strains Lactobacillus johnsonii KCTC 3801 T , Lactobacillus plantarum KCTC 3108 T , Bifidobacterium
- Lactobacillus johnsonii IDCC9203 No. 6
- Lactobacillus plantarum IDCC3501 No. 7
- Bifidobacterium animalis subspecies lactis IDCC4301 No. 14 strains, including various individual lactic acid strains were administered to LPS-treated Raw 264.7 cells, and NO. The results of confirming the ability to inhibit (nitrogen oxide) are shown.
- FIG. 7 shows the DAI score when administered with the three lactic acid bacteria formulations of the present invention to an animal model of colitis, by dose, and sulfasalazine, a known treatment for IBD, was used as a comparative group.
- FIG. 8 is an image of observing the length of the colon when the three types of lactic acid bacteria preparations of the present invention were administered to an animal model of colitis, and sulfasalazine, a known IBD therapeutic agent, was used as a comparative group.
- Figure 9 shows the results of measuring the length of the colon when the three types of lactic acid bacteria preparations of the present invention are administered to an animal model of colitis, by dose, and sulfasalazine, a known treatment for IBD, was used as a comparative group.
- FIG. 10 is an image observing a cross-sectional tissue of the large intestine when the three types of lactic acid bacteria preparations of the present invention were administered to an animal model of colitis.
- 11 is a comparative histological score for colon tissue damage when the three lactic acid bacteria preparations of the present invention are administered to an animal model of colitis, and sulfasalazine, a known IBD therapeutic agent, was used as a control group.
- FIG. 12 shows the results of measuring the level of TNF- ⁇ in the colon when the three types of lactic acid bacteria preparations of the present invention are administered to an animal model of colitis, by dose, and sulfasalazine, a known IBD therapeutic agent, was used as a comparative group.
- FIG. 13 shows the results of measuring the level of IL-1 ⁇ in the colon when administered with the three lactic acid bacteria preparations of the present invention to an animal model of colitis, and sulfasalazine, a known IBD therapeutic agent, was used as a comparative group.
- FIG. 14 shows the results of measuring the level of IL-6 in the large intestine when the three lactic acid bacteria preparations of the present invention were administered to an animal model of colitis, and sulfasalazine, a known IBD therapeutic agent, was used as a comparative group.
- Fig. 15 shows the DAI score when the three types of lactic acid bacteria preparations or the V company lactic acid bacteria preparations of the present invention are administered to an animal model of colitis.
- Fig. 16 shows an image of observing the length of the large intestine when the three types of lactic acid bacteria preparations of the present invention or the V company lactic acid bacteria preparations are administered to a colitis animal model.
- Fig. 17 shows the results of measuring the length of the large intestine when the three types of lactic acid bacteria preparations or the V company lactic acid bacteria preparations of the present invention are administered to an animal model of colitis.
- Fig. 18 shows histological scores for colon tissue damage when the three types of lactic acid bacteria preparations of the present invention or the V company lactic acid bacteria preparations are administered to an animal model of colitis.
- Fig. 20 shows the results of measuring the level of IL-1 ⁇ in the colon when the three types of lactic acid bacteria preparations or the V company lactic acid bacteria preparations of the present invention are administered to an animal model of colitis.
- Fig. 21 shows the results of measuring the level of IL-6 in the large intestine when the three types of lactic acid bacteria preparations of the present invention or the V company lactic acid bacteria preparations are administered to an animal model of colitis.
- Example 2 Confirmation of the anti-inflammatory synergistic effect of the three lactic acid bacteria preparations (mixture ) of the present invention , and comparison of the specificity of the strain combination
- Lactobacillus johnsonii IDCC9203 (No. 6 in Fig. 1), Lactobacillus plantarum IDCC3501 (No. 7 in Fig. 1) and Bifidobacterium
- Each animalis subspecies lactis IDCC4301 (No. 14 in FIG. 1) was incubated at 37° C. for 2 hours in MRS broth, and then the cells were collected by centrifugation at 10,000 ⁇ g for 15 minutes. After washing the cells twice with 1X PBS buffer, the samples were heat-killed at 100° C. for 10 minutes to kill the cells and then used for anti-inflammatory effect analysis.
- the dead cell mixture for the three kinds of lactic acid bacteria is mixed by mixing each of the killed strains in a ratio of 1: 1: 1 based on CFU Was manufactured.
- RAW 264.7 cells mouse macrophages, were phenol red-free Dulbecco's modified containing 10% fetal bovine serum (FBS, Atlas, Fort Collins, CO, USA) and 1% penicillin (Sigma-Aldrich, St. Lousi, MO, USA).
- Eagle medium DMEM, Gibco-BRL, Gaithersburg, MD, USA was cultured at 37°C and 5% CO 2 conditions.
- the cultured Raw 264.7 cells were recovered using a scraper or trypsinize, and then placed in a 15 ml falcon tube at 500 rpm. It was centrifuged for 5 minutes. After removing the supernatant, 1 ml of complete media was added and resuspended to count the number of cells per ml. 2 ml of the diluted cell solution was added to each well of a 6-well plate and cultured overnight for 24 hours. After suctioning the medium of each well in a 6-well plate, it was washed with PBS.
- the supernatant of each tube was separately collected and used for cytokine experiments.
- As an inflammatory cytokine it was confirmed by using an ELISA kit (R&D system) whether or not to suppress the production of TNF- ⁇ , IL-6, and IL-1 ⁇ representatively.
- FIG. 6 is a comparison of the efficacy of individual strains on the inhibition of NO (nitrogen oxide) production
- Lactobacillus johnsonii IDCC9203 No. 6 in FIGS. 1 and 6
- Lactobacillus plantarum IDCC3501 No. 7 in FIGS. 1 and 6
- animalis subspecies lactis IDCC4301 including (in Figs. 1 and 6 No.14) shows the experimental results for some representative strain with a relatively.
- the experimental method is simply as follows. Each of the lactic acid bacteria was cultured by the above-described general culture method, and after the culture was completed, the cells were centrifuged to obtain the cells, and the cells were killed by heat-killed treatment at 100° C. for 15 minutes.
- RAW 264.7 cells (1 ⁇ 10 5 /mL) were first cultured in DMEM, LPS (2 ⁇ l/ml) and each heat-killed cells (1 ⁇ 10 5 cells/mL) were treated, and then 24 hours. During incubation. The concentration of NO was investigated by measuring the amount of nitrite in the cell culture supernatant according to the manufacturer's protocol using Griess reagent (Sigma, USA).
- Lactobacillus johnsonii IDCC9203 No. 6 in FIGS. 1 and 6
- Lactobacillus plantarum IDCC3501 No. 7 in FIGS. 1 and 6
- Bifidobacterium which are the constituents of the present invention animalis subspecies lactis IDCC4301 (No. 14 in FIGS. 1 and 6) was remarkably excellent in inhibiting NO production compared to other lactic acid bacteria strains (see FIG. 6).
- Example 3 3 kinds of lactic acid bacteria probiotic preparation of the present invention in vivo IBD (Inflammatory bowel disease) treatment efficacy confirmed & compared with sulfasalazine, an IBD treatment compound
- the three lactic acid bacteria probiotic preparations of the present invention used in the experiment consisted of three live bacterial strains of Lactobacillus johnsonii IDCC9203 (KCTC 10923BP), Lactobacillus plantarum IDCC3501 (KCTC 13586BP) and Bifidobacterium animalis subspecies lactis IDCC4301 (KCTC 13587BP). It was prepared by mixing in a standard 1: 1: 1 ratio. Each viable strain contained 2x10 12 CFU/g each. Each bacteria was incubated in a growth medium at 37°C for 16 hours until the exponential phase was reached, and then the bacterial pellets were stored in a freeze dryer and freeze-dried (under vacuum conditions at -80°C. , overnight). The freeze-dried three lactic acid bacteria preparations of the present invention were stored at 4°C until use.
- mice Female BALB/c mice (8 weeks old) were purchased from Orient Bio (Seongnam, Republic of Korea). Five animals per cage were housed in an environmental control facility (temperature 22° C. ⁇ 2° C., humidity 55% ⁇ 5%) with a 12/12 h light/dark cycle. Animal care and treatment was carried out in accordance with the guidelines established by the'National Institutes of Health Animal Research and Care' and approved by the Institutional Animal Care and Use Committee of Ildong Pharmaceutical Co., Ltd. Number: A1611-2) approved.
- mice were divided into 7 groups (10 mice per group), and the average of the initial body weight (BW) was similarly adjusted.
- DSS was dissolved in drinking water at a concentration of 3.5% (w/v), and all mice except the normal group were supplied from day-0 to day-8. Animals were free to consume water and diet.
- DW distilled water
- the three lactic acid bacteria formulations of the present invention are 10 6 CFU/mice/day- 10 9 CFU/mice/day dose range, sulfasalazine (Tokyo chemical industry, Tokyo, Japan) as a positive control at a concentration of 500 mg/kg (BW)/day, suspended in DW and then in the same volume and method as the vehicle group.
- BW 500 mg/kg
- BW body weight
- stool conditions were observed for each mouse once a day, and DAI (disease activity index) score was calculated according to the criteria shown in Table 2 below, as in a known method.
- the maximum value that can be calculated according to Table 2 below was 12.
- the large intestine (colon) from the ileocecal junction to the anus was removed to measure the length, and washed with PBS (phosphate buffered saline) to remove residual digestive products in the intestine.
- PBS phosphate buffered saline
- a third of the distal colon was fixed with a 10% formaldehyde solution and used for histopathological analysis. The remaining two-thirds of the distal colon tissue was used for protein extraction to measure proinflammatory cytokine levels and stored at -80°C until use.
- the colon tissue was fixed with a 10% neutral buffered formaldehyde solution and treated with paraffin embedding in a conventional manner. Paraffin-embedded tissue sections were cut to a thickness of 4 ⁇ m and stained with hematoxylin & eosin (H&E). H&E-stained colon tissue was observed at 100x and 200x magnifications using a Nikon ECLIPSE 50i optical microscope (Nikon, Tokyo, Japan), and according to conventionally known parameters as described in Table 3 (Histological Scoring System). Histological evaluation was performed by two pathologists. According to Table 3, the maximum score calculated by summing each of the three parameters was 10.
- the colon proteins were extracted using RIPA buffer (Upstate, Temesula, CA, USA) to which a protease inhibitor (Sigma-Aldrich, St. Louis, MO, USA) was added. After adding 300 ⁇ l of RIPA buffer to the colon tissue, the tissue was homogenized on ice for 1 minute and centrifuged at 20,000 g for 15 minutes at 4°C. After collecting the supernatant, it was quantified using a bicinchoninic acid protein assay reagent kit (Pierce, Rockford, IL, USA).
- ELISA kit (R&D Systems, Minneapolis, MN, USA) was used according to the manufacturer's protocol to detect levels of pro-inflammatory cytokines such as TNF-a, IL-1b and IL-6 in colon tissue. Each cytokine value was corrected for the total amount of each colon protein sample.
- Results are presented as mean ⁇ standard error, and each result was processed using Prism 7 (GraphPad Software, San Diego, CA, USA), a statistical analysis system. All results represent the average of at least three independent experiments. Statistical comparisons between the vehicle group and each treatment group were performed by one-way analysis of variance and subsequent Dunnett's test. P value ⁇ 0.05 was considered statistically significant.
- the DAI score of the group administered with the three lactic acid bacteria formulations of the present invention at a dose of 10 8 CFU/mice/day or 10 9 CFU/mice/day was similar to the DAI sore of the sulfasalazine administration group.
- the length of the colon was shorter than that of the normal group.
- These symptoms of shortening of the bowel length were dose-dependently prevented by the three lactic acid bacteria preparations of the present invention, and the three lactic acid bacteria preparations of the present invention 10 8 CFU/mice/day or 10 9 CFU/mice/day in the dose administration group and the sulfasalazine administration group
- the liver showed an equivalent effect pattern (see FIGS. 8 and 9).
- histological score was measured. As shown in FIGS. 10 and 11, invasion of inflammatory cells in mucous membranes and submucosal tissues, severe intestinal crypt damage, loss of goblet cells and epithelial cells were observed in the vehicle group. Also, histological score increased to 7.2 ⁇ 0.6. On the other hand, histological scores in the sulfasalazine-administered group decreased sharply. In the group treated with three types of lactic acid bacteria of the present invention, the histological score decreased in a dose-dependent manner.
- the histological score of colon damage was significantly reduced in the three lactic acid bacteria formulations of the present invention in the 10 8 CFU/mice/day administration group and the 10 9 CFU/mice/day administration group (5.2 ⁇ 0.5 and 4.9 ⁇ 0.6, respectively), which is sulfasalazine It was similar to that in the administration group (4.5 ⁇ 0.5).
- ELISA was performed. Representatively, expression patterns of three pro-inflammatory cytokines such as TNF- ⁇ , IL-1 ⁇ and IL-6 were investigated, and they are known to play an important role in colitis pathology. As shown in FIGS. 12, 13 and 14, the expression level of each of the cytokines was increased in the colitis pathology state, but decreased in a dose-dependent manner by administration of the three lactic acid bacteria formulations of the present invention. Compared with the sulfasalazine administration group used as a positive control, the three lactic acid bacteria formulations of the present invention 10 9 CFU/mice/day administration group showed similar inhibitory effects.
- Example 4 IBD Existing market approved for Probiotics Comparative evaluation of the efficacy of the product and the three lactic acid bacteria formulations of the present invention for treatment of inflammatory bowel
- lactic acid bacteria formulation of V a probiotic product that has been individually recognized by the Ministry of Food and Drug Safety to help regulate intestinal immunity to improve inflammatory bowel disease (IBD). The effect was compared with the three lactic acid bacteria probiotic preparations (mixture) of the present invention.
- the lactic acid bacteria formulation of the company V is in hanpo It is known to consist of a total of about 450 billion (4.5 ⁇ 10 11 bacteria/bag) of live bacteria, specifically Lactobacillus paracasei DSM 24734 , Lactobacillus plantarum DSM 24730 , Lactobacillus acidophilus DSM 24735 , Lactobacillus delbrueckii subsp.
- thermophilus DSM 24731 is known to contain 8 viable strains.
- composition of the test group was performed as shown in Table 4 below, and at this time, a mixture of the above-described three strains as a mixture of three lactic acid bacteria of the present invention in a ratio of 1:1: 1 based on CFU was used in a representative experiment. In addition to the conditions described in Table 4 below, the remaining experimental methods were performed in the same manner as in Example 3.
- Dosage Normal Control 10 1st distilled water p.o 10 mL/kg/day 0 mg/kg/day Vehicle 10 1st distilled water with 3.5% DSS added p.o 10 mL/kg/day 0 mg/kg/day Company V lactic acid bacteria preparation 10 p.o 200ul/mouse/day 5.4x10 8 CFU/day Invention 10 8 10 p.o 200ul/mouse/day 10 8 CFU/day Invention 10 9 10 p.o 200ul/mouse/day 10 9 CFU/day
- the three types of lactic acid bacteria formulation of the present invention and the group V lactic acid bacteria formulation of the present invention showed the effect of preventing weight loss, improving the appearance of excreta, and improving blood stool, thereby reducing the DAI score.
- DAI socre was compared with the V company lactic acid bacteria formulation, despite being administered at a lower CFU dose compared to the 5.4 ⁇ 10 8 CFU administration group of the company V. So it was reduced to an equivalent level.
- the present invention relates to a novel probiotic composition for regulating intestinal immunity, and more particularly, Lactobacillus johnsonii , Lactobacillus plantarum , and Bifidobacter Leeum animalis subspecies lactis ( Bifidobacterium animalis subspecies lactis ) It is for a composition for preventing, improving, or treating inflammation and/or inflammatory bowel disease containing as an active ingredient.
- composition comprising the combination of three lactic acid bacteria unique to the present invention has a remarkable preventive and therapeutic effect on inflammatory bowel disease (IBD), and in particular, this effect is pharmacologically superior even compared to a known IBD therapeutic drug (for example, sulfasalazine).
- IBD inflammatory bowel disease
- the composition of the present invention has a great advantage as a safe composition with very little risk of side effects due to the nature of a probiotic composition, and thus has high industrial applicability.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
군(group) | 동물수 | 식음수 | 투여경로 | 투여액량 | 투여량 |
Normal Control | 10 | 1차 증류수 | p.o | 10 mL/kg/day | 0 mg/kg/day |
Vehicle | 10 | 3.5% DSS가 첨가된 1차 증류수 | p.o | 10 mL/kg/day | 0 mg/kg/day |
V사 유산균 제제 | 10 | p.o | 200ul/mouse/day | 5.4x10 8CFU/day | |
본 발명 10 8 | 10 | p.o | 200ul/mouse/day | 10 8CFU/day | |
본 발명 10 9 | 10 | p.o | 200ul/mouse/day | 10 9CFU/day |
Claims (12)
- 락토바실러스 존소니( Lactobacillus johnsonii), 락토바실러스 플란타룸( Lactobacillus plantarum) 및 비피도박테리움 아니말리스 아종 락티스( Bifidobacterium animalis subspecies lactis)를 유효성분으로 포함하는 염증성 장질환의 예방 또는 치료용 약학적 조성물.
- 제1항에 있어서, 상기 조성물은 락토바실러스 존소니 IDCC9203 균주, 락토바실러스 플란타룸 IDCC3501 균주 및 비피도박테리움 아니말리스 아종 락티스 IDCC4301 균주를 포함하는 것을 특징으로 하는 조성물.
- 제1항에 있어서, 상기 락토바실러스 존소니, 락토바실러스 플란타룸 및 비피도박테리움 아니말리스 아종 락티스는 각각 생균 또는 사균인 것을 특징으로 하는 조성물.
- 락토바실러스 존소니( Lactobacillus johnsonii), 락토바실러스 플란타룸( Lactobacillus plantarum), 및 비피도박테리움 아니말리스 아종 락티스( Bifidobacterium animalis subspecies lactis)를 유효성분으로 포함하는 염증성 장질환의 예방 또는 개선용 식품 조성물.
- 제4항에 있어서, 상기 락토바실러스 존소니, 락토바실러스 플란타룸 및 비피도박테리움 아니말리스 아종 락티스는 각각 생균 또는 사균인 것을 특징으로 하는 조성물.
- 락토바실러스 존소니( Lactobacillus johnsonii), 락토바실러스 플란타룸( Lactobacillus plantarum), 및 비피도박테리움 아니말리스 아종 락티스( Bifidobacterium animalis subspecies lactis)를 유효성분으로 포함하는 항염증용 약학적 조성물.
- 락토바실러스 존소니( Lactobacillus johnsonii), 락토바실러스 플란타룸( Lactobacillus plantarum), 및 비피도박테리움 아니말리스 아종 락티스( Bifidobacterium animalis subspecies lactis)를 유효성분으로 포함하는 항염증용 식품 조성물.
- 염증성 장질환의 예방 또는 치료용 제제를 제조하기 위한 락토바실러스 존소니( Lactobacillus johnsonii), 락토바실러스 플란타룸( Lactobacillus plantarum) 및 비피도박테리움 아니말리스 아종 락티스( Bifidobacterium animalis subspecies lactis)를 유효성분으로 포함하는 조성물의 용도.
- 락토바실러스 존소니( Lactobacillus johnsonii), 락토바실러스 플란타룸( Lactobacillus plantarum) 및 비피도박테리움 아니말리스 아종 락티스( Bifidobacterium animalis subspecies lactis)를 유효성분으로 포함하는 조성물의 유효량을 이를 필요로 하는 개체에 투여하는 단계를 포함하는 염증성 장질환의 치료 방법.
- 제9항에 있어서, 상기 염증성 장질환은 크론병, 궤양성 대장염, 장관 베체트병 및 허혈성 장염으로 이루어지는 군에서 하나 이상 선택되는 것을 특징으로 하는 방법.
- 항염증용 제제를 제조하기 위한 락토바실러스 존소니( Lactobacillus johnsonii), 락토바실러스 플란타룸( Lactobacillus plantarum), 및 비피도박테리움 아니말리스 아종 락티스( Bifidobacterium animalis subspecies lactis)를 유효성분으로 포함하는 조성물의 용도.
- 락토바실러스 존소니( Lactobacillus johnsonii), 락토바실러스 플란타룸( Lactobacillus plantarum), 및 비피도박테리움 아니말리스 아종 락티스( Bifidobacterium animalis subspecies lactis)를 유효성분으로 포함하는 조성물의 유효량을 이를 필요로 하는 개체에 투여하는 단계를 포함하는 염증 억제 방법.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2019454505A AU2019454505B2 (en) | 2019-06-27 | 2019-07-23 | Novel probiotic composition for regulation of intestinal immunity |
US17/622,177 US20220409677A1 (en) | 2019-06-27 | 2019-07-23 | Novel probiotic composition for regulation of intestinal immunity |
EP19935091.9A EP3991739A4 (en) | 2019-06-27 | 2019-07-23 | NEW PROBIOTIC COMPOSITION TO REGULATE INTESTINAL IMMUNITY |
JP2021577227A JP7434375B2 (ja) | 2019-06-27 | 2019-07-23 | 腸管免疫調節のための新規なプロバイオティック組成物 |
BR112021026278A BR112021026278A2 (pt) | 2019-06-27 | 2019-07-23 | Composições farmacêuticas, composições alimentícias, usos de uma composição, método de tratamento da doença inflamatória intestinal e método para inibir a inflamação |
CA3145236A CA3145236C (en) | 2019-06-27 | 2019-07-23 | Novel probiotic composition for regulation of intestinal immunity |
CN201980099516.7A CN114786692A (zh) | 2019-06-27 | 2019-07-23 | 用于调节肠道免疫的新型益生菌组合物 |
IL289377A IL289377A (en) | 2019-06-27 | 2021-12-26 | A probiotic preparation for regulating intestinal immunity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190077422 | 2019-06-27 | ||
KR10-2019-0077422 | 2019-06-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020262755A1 true WO2020262755A1 (ko) | 2020-12-30 |
Family
ID=74059744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2019/009117 WO2020262755A1 (ko) | 2019-06-27 | 2019-07-23 | 장관면역 조절을 위한 신규한 프로바이오틱 조성물 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220409677A1 (ko) |
EP (1) | EP3991739A4 (ko) |
JP (1) | JP7434375B2 (ko) |
KR (1) | KR102475432B1 (ko) |
CN (1) | CN114786692A (ko) |
AU (1) | AU2019454505B2 (ko) |
BR (1) | BR112021026278A2 (ko) |
CA (1) | CA3145236C (ko) |
IL (1) | IL289377A (ko) |
WO (1) | WO2020262755A1 (ko) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113151039A (zh) * | 2021-01-14 | 2021-07-23 | 江南大学 | 一株缓解溃疡性结肠炎的植物乳杆菌及其应用 |
CN114276958A (zh) * | 2021-12-20 | 2022-04-05 | 无锡弘焕微生态科技有限公司 | 具有抗炎功效的三重益生菌发酵复合物的制备方法和应用 |
CN115210360A (zh) * | 2021-02-09 | 2022-10-18 | 乐土美森有限公司 | 源自母乳的新型罗伊氏乳杆菌lm1071菌株,以及包含所述菌株或其培养物的用于缓解经前期综合征的组合物 |
WO2023021141A1 (en) * | 2021-08-19 | 2023-02-23 | Société des Produits Nestlé S.A. | Postbiotic |
WO2023021140A1 (en) * | 2021-08-19 | 2023-02-23 | Société des Produits Nestlé S.A. | Postbiotic |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140037544A (ko) * | 2012-09-19 | 2014-03-27 | 주식회사 쎌바이오텍 | 과민성 대장 증후군 예방 또는 치료용 조성물 |
KR20150095717A (ko) * | 2012-12-18 | 2015-08-21 | 꽁빠니 자베 다노느 | 비피도박테리움 아니말리스 아종 아니말리스 균주 |
KR20190048739A (ko) * | 2017-10-31 | 2019-05-09 | 일동제약(주) | 염증의 예방 또는 개선 효능을 갖는 락토바실러스 존소니 아디씨씨 9203 및 이의 용도 |
KR20190077422A (ko) | 2016-11-11 | 2019-07-03 | 다우 글로벌 테크놀로지스 엘엘씨 | 이산화탄소와 옥시란의 공중합화를 통한 폴리카보네이트 폴리올을 제조하기 위한 반 회분식 공정 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201701891A (zh) * | 2015-02-27 | 2017-01-16 | Meiji Co Ltd | 大腸炎抑制劑 |
KR20190048732A (ko) * | 2017-10-31 | 2019-05-09 | 일동제약(주) | 염증의 예방 및 치료 효과를 갖는 락토바실러스 존소니 아이디씨씨 9203 및 이의 용도 |
-
2019
- 2019-07-23 BR BR112021026278A patent/BR112021026278A2/pt unknown
- 2019-07-23 CA CA3145236A patent/CA3145236C/en active Active
- 2019-07-23 AU AU2019454505A patent/AU2019454505B2/en active Active
- 2019-07-23 JP JP2021577227A patent/JP7434375B2/ja active Active
- 2019-07-23 EP EP19935091.9A patent/EP3991739A4/en active Pending
- 2019-07-23 US US17/622,177 patent/US20220409677A1/en active Pending
- 2019-07-23 CN CN201980099516.7A patent/CN114786692A/zh active Pending
- 2019-07-23 WO PCT/KR2019/009117 patent/WO2020262755A1/ko active Application Filing
-
2020
- 2020-06-26 KR KR1020200078483A patent/KR102475432B1/ko active IP Right Grant
-
2021
- 2021-12-26 IL IL289377A patent/IL289377A/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140037544A (ko) * | 2012-09-19 | 2014-03-27 | 주식회사 쎌바이오텍 | 과민성 대장 증후군 예방 또는 치료용 조성물 |
KR20150095717A (ko) * | 2012-12-18 | 2015-08-21 | 꽁빠니 자베 다노느 | 비피도박테리움 아니말리스 아종 아니말리스 균주 |
KR20190077422A (ko) | 2016-11-11 | 2019-07-03 | 다우 글로벌 테크놀로지스 엘엘씨 | 이산화탄소와 옥시란의 공중합화를 통한 폴리카보네이트 폴리올을 제조하기 위한 반 회분식 공정 |
KR20190048739A (ko) * | 2017-10-31 | 2019-05-09 | 일동제약(주) | 염증의 예방 또는 개선 효능을 갖는 락토바실러스 존소니 아디씨씨 9203 및 이의 용도 |
Non-Patent Citations (9)
Title |
---|
ANONYMOUS: "Intercourse. Intestinal Health of People Protected by Probiotics Today.", 25 October 2018 (2018-10-25), pages 1 - 4, Retrieved from the Internet <URL:http://kr.ifeng.com/a/20181025/6972781_0.shtml> * |
ATREYA RZIMMER MBARTSCH B ET AL.: "Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14(+) macrophages", GASTROENTEROLOGY, vol. 141, 2011, pages 2026 - 2038, XP028118482, DOI: 10.1053/j.gastro.2011.08.032 |
CHINA ECONOMIC NET: "South Korea develops new probiotics that may improve symptoms of irritable bowel syndrome", 27 September 2018 (2018-09-27), pages 1 - 3, XP009532625, Retrieved from the Internet <URL:http://qiye.chinadaily.com.cn/2018-09/27/content_36988113.htm> * |
COCCIA MHARRISON OJSCHIERING C ET AL.: "IL-1 beta mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells", J EXP MED, vol. 209, 2012, pages 1595 - 1609 |
ILDONGPHARMACEUTICAL CO., LTD. ET AL.: "Final report on the development and global branding of Korean probiotics effective for irritable bowel syndrome ", FINAL REPORT, 25 September 2019 (2019-09-25), Korea, pages 1 - 351, XP009532633 * |
JE IN-GYU, LEE DON-GIL, JEONG DONG-GU, HONG DAHAE, YOON JONG-MIN, MOON JIN SEOK, PARK SOOBONG: "The probiotic, ID-JPL934, attenuates dextran sulfate sodium-induced colitis in mice through inhibition of proinflammatory cytokines expression.", JOURNAL OF MEDICINAL FOOD., vol. 21, no. 9, 23 July 2018 (2018-07-23), pages 858 - 865, XP055778837 * |
JE IN-GYU, LEE DON-GIL, JEONG DONG-GU, HONG DAHAE, YOON JONG-MIN, MOON JIN SEOK, PARK SOOBONG: "The probiotic, ID-JPL934, attenuates dextran sulfate sodium-induced colitis in mice through inhibition of proinflammatory cytokines expression.", POSTER NO. C041, IN: 2019 INTERNATIONAL MEETING OF THE MICROBIOLOGICAL SOCIETY OF KOREA ., 17 April 2019 (2019-04-17), Jeju, Korea, pages 858 - 865, XP055778837 * |
SHIN CHEOL MIN; CHOI YOON JIN; LEE DONG HO; YOON HYUK; PARK YOUNG SOO; KIM NAYOUNG: "Sa1951 - Validity and Safety of Symptom Improvement of Id-Jpl934 for Abnormal Bowel Movements Such As Constipation, Diarrhea, Abdominal Pain: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial", GASTROENTEROLOGY, vol. 156, no. 6, 18 May 2019 (2019-05-18), pages S-466 - S-466, XP085678040, ISSN: 0016-5085, DOI: 10.1016/S0016-5085(19)38017-5 * |
WANG YWANG KHAN GC ET AL.: "Neutrophil infiltration favors colitis-associated tumorigenesis by activating the interleukin-1 (IL-1)/IL-6 axis", MUCOSAL IMMUNOL, vol. 7, 2014, pages 1106 - 1115 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113151039A (zh) * | 2021-01-14 | 2021-07-23 | 江南大学 | 一株缓解溃疡性结肠炎的植物乳杆菌及其应用 |
CN115210360A (zh) * | 2021-02-09 | 2022-10-18 | 乐土美森有限公司 | 源自母乳的新型罗伊氏乳杆菌lm1071菌株,以及包含所述菌株或其培养物的用于缓解经前期综合征的组合物 |
WO2023021141A1 (en) * | 2021-08-19 | 2023-02-23 | Société des Produits Nestlé S.A. | Postbiotic |
WO2023021140A1 (en) * | 2021-08-19 | 2023-02-23 | Société des Produits Nestlé S.A. | Postbiotic |
CN114276958A (zh) * | 2021-12-20 | 2022-04-05 | 无锡弘焕微生态科技有限公司 | 具有抗炎功效的三重益生菌发酵复合物的制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN114786692A (zh) | 2022-07-22 |
CA3145236C (en) | 2024-03-26 |
KR102475432B1 (ko) | 2022-12-07 |
US20220409677A1 (en) | 2022-12-29 |
AU2019454505B2 (en) | 2023-07-20 |
JP7434375B2 (ja) | 2024-02-20 |
KR20210002032A (ko) | 2021-01-06 |
AU2019454505A1 (en) | 2022-02-17 |
EP3991739A4 (en) | 2023-07-05 |
IL289377A (en) | 2022-02-01 |
BR112021026278A2 (pt) | 2022-03-03 |
JP2022539139A (ja) | 2022-09-07 |
CA3145236A1 (en) | 2020-12-30 |
EP3991739A1 (en) | 2022-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020262755A1 (ko) | 장관면역 조절을 위한 신규한 프로바이오틱 조성물 | |
WO2019226003A1 (ko) | 락토바실러스 가세리 kbl697 균주 및 그 용도 | |
WO2015122717A1 (ko) | 비만 억제 효능을 갖는 신규 유산균 및 이의 용도 | |
WO2017204374A1 (ko) | 혈당 조절 효능을 갖는 신규 유산균 및 이의 용도 | |
WO2021221398A1 (ko) | 우수한 면역기능 증진 효과를 갖는 신규한 유산균 및 이를 포함하는 식품조성물, 건강기능성 식품 조성물 및 프로바이오틱스 | |
WO2018093238A2 (ko) | 포름산 생성능이 우수한 균주를 유효성분으로 포함하는 비만 또는 비만으로 야기된 대사증후군의 예방 또는 치료용 조성물 | |
WO2018062914A1 (ko) | 신규한 락토바실러스 사케이 및 이를 포함하는 조성물 | |
WO2021194225A1 (ko) | 락토바실러스 델브루키 subsp. 락티스 CKDB001 균주, 및 이를 포함하는 비알코올성 지방간의 예방, 개선, 또는 치료용 조성물 | |
WO2019199094A1 (ko) | 비만의 예방 또는 치료 효과를 가지는 신규 비피도박테리움 롱검 균주 또는 락토바실러스 람노서스 균주 및 이의 용도 | |
WO2020091312A1 (ko) | 프로바이오틱스를 유효성분으로 포함하는 알코올성 장손상 예방 또는 치료용 조성물 | |
WO2022145807A1 (ko) | 신규한 비피도박테리움 애니멀리스 락티스 hem20-01 균주, 및 상기 균주 또는 이의 배양물을 포함하는 우울증 치료용 조성물 | |
WO2021066549A1 (ko) | 락토바실러스 애시도필러스 kbl409 균주 및 그 용도 | |
WO2017131402A1 (ko) | 면역조절 작용을 가는 사람 소화관 유래 신규 유산균 및 이의 용도 | |
WO2021075663A1 (ko) | 락토바실러스 헬베티커스 및 비피도박테리움 균주를 포함하는 비알코올성 지방간질환의 예방, 개선, 또는 치료용 조성물 | |
WO2017047962A1 (ko) | 신규 유산균 및 퇴행성 뇌질환 또는 인지기능 장애의 예방, 개선 또는 치료용 조성물 | |
WO2023055188A1 (ko) | 신규 프로바이오틱스 및 이의 용도 | |
WO2020013670A1 (ko) | 락토바실러스 플란타럼 cjlp475 균주 및 락토바실러스 플란타럼 cjlp17 균주를 포함하는 조성물 및 이의 용도 | |
WO2019225953A2 (ko) | 잣나무 부산물 추출물을 함유하는 헬리코박터파일로리균 제균 효과를 갖는 조성물 | |
WO2019117654A1 (ko) | 신장질환 진행 억제 및 예방용 프로바이오틱스 및 이를 포함하는 신장질환 진행 억제 및 예방용 조성물 | |
WO2014196775A1 (ko) | 락토바실러스 브레비스 g-101 및 이의 용도 | |
WO2024048934A1 (ko) | 체지방 감소용 신규 유산균 락티플랜티바실러스 플란타룸 sko-001 및 이의 용도 | |
WO2016010340A1 (ko) | 오풍칠 추출물을 유효성분으로 함유하는 염증 또는 알러지 질환의 예방 및 치료용 조성물 및 이의 용도 | |
WO2020139020A2 (ko) | 헬리코박터 파일로리 연관 질환의 예방 또는 치료용 김치 | |
WO2020013672A1 (ko) | 락토바실러스 플란타럼 cjlp475 균주 및 락토바실러스 플란타럼 cjlp243 균주를 포함하는 조성물 및 이의 용도 | |
WO2023068855A1 (ko) | 항암 활성을 갖는 베일로넬라 파르불라 균주를 이용한 암의 완화, 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19935091 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3145236 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021577227 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021026278 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2019935091 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2019935091 Country of ref document: EP Effective date: 20220127 |
|
ENP | Entry into the national phase |
Ref document number: 2019454505 Country of ref document: AU Date of ref document: 20190723 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112021026278 Country of ref document: BR Kind code of ref document: A2 Effective date: 20211223 |